Effect of tumor size on survival in pN0M0 non-small cell lung cancer patients

Year 2016, Volume: 1 Issue: 1, 12 - 15, 28.12.2016

Gökhan Kocaman Cabir Yüksel , Bülent Mustafa Yenigün Mehmet Ali Sakallı Durdu Karasoy Murat Özkan Serkan Enön Ayten Kayı Cangır

Abstract

Background: Tumor size is one of the major prognostic determinants of non-small cell lung cancer (NSCLC). In the present study, we evaluated the effect of tumor size on survival in pN0M0 NSCLC patients.

Materials and Methods: Between 1994 and 2013, 1975 NSCLC patients underwent surgery in our center. The study included 774 NSCLC patients with pathological stage N0M0, and these patients were divided into 8 groups according to tumor diameter, as follows, Group 1: 0-10 mm, Group 2: 11-20 mm, Group 3: 21-30 mm, Group 4: 31-40 mm, Group 5: 41-50 mm, Group 6: 51-60 mm, Group 7: 61-70 mm, and Group 8: > 70 mm. We aimed to evaluate the prognostic effect of tumor size on overall survival and to determine a cut-off point for tumor size.

Results: The 5 year overall survival rate for groups 1 to 8 were 85.6%, 81.3%, 68.6%, 62.2%, 55%, 54.2%, 54.3%, and 45.6%, respectively. The mean follow-up time was 43.8 months. In multivariate analysis, age, tumor size, and surgical resection type had an independent prognostic value on survival.

Conclusions: Tumor size is an independent prognostic factor for pN0M0 NSCLC patients. A tumor size of 4 cm was found to be the most suitable cut-off point for survival which may be of help in decision-making for adjuvant chemotherapy.

Keywords

Non-small cell lung cancer, tumor size, survival

References

• Rami-Porta R, Bolejack V, Crowley J, Ball D, Kim J, Lyons G, et al. IASLC Staging and Prognos¬tic Factors Committee, Advisory Boards and Participating Institutions. The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 2015; 10:990-1003.
• Zhang J, Gold AK, Lin HY, Swisher SG, Xing Y, Lee JJ, et al. Relationship between tumor size and survival in non-small cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol 2015; 10:682-90.
• Okada M, Koike T, Higashiyama M, Yamato Y, Kodama K, Tsubota N. Radical sublobar resection for small-sized non–small cell lung cancer: A multicenter study. J Thorac Cardiovasc Surg 2006; 132:769-75.
• Sihoe ADL, Van Schil P. Non-small cell lung cancer: When to offer sublobar resection. Lung Cancer 2016; 84:115-20.
• Takeda S-i, Fukai S, Komatsu H, Nemoto E, Nakamura K, Murakami M. Impact of large tumor size on survival after resection of pathologically node negative (pN0) non-small cell lung cancer. Ann Thorac Surg 2005; 79:1142-6.
• Cangır AK, Kutlay H, Akal M, Güngör A, Özdemir N, Akay H. Prognostic value of tumor size in non-small cell lung cancer larger than five centimeters in diameter. Lung Cancer 2004; 26:325-31.
• Zhang Y, Sun Y, Chen H. Effect of tumor size on prognosis of node-negative lung cancer with sufficent lymph node examination and no disease extension. Onco Targets and Therapy 2016; 9:649-53.
• Speicher PJ, Gu L, Wang X, Hartwig MG, D’Amico TA, Berry MF. Adjuvant chemotherapy after lobectomy for T1-2N0 non-small cell lung cancer: are the guidelines supported? J Natl Compr Canc Netw 2015; 13:755-61.
• Malhotra J, Mhango G, Gomez JE, Smith C, Galsky MD, Strauss GM, et al. Adjuvant chemotherapy for elderly patients with stage I non-small-cell lung cancer ≥4 cm in size: an SEER-Medicare analysis. Ann Oncol 2015; 26:768-73.
• Strauss GM, Herndon II JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non–small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26:5043-51.